ArticleBMC health services research2023

Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia.

Mansour A Alharbi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.